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Background: HDL-C plasma levels are modulated by dietary fatty acid (FA), but studies investigating
dietary supplementation in FA gave contrasting results. Saturated FA increased HDL-C levels only in some
studies. Mono-unsaturated FA exerted a slight effect while poly-unsaturated FA mostly increased plasma
HDL-C.
Aims: This study presents two aims: i) to investigate the relationship between HDL-C levels and plasma
FA composition in a Sicilian population following a “Mediterranean diet”, ii) to investigate if FA that
resulted correlated with plasma HDL-C levels in the population study and/or very abundant in the
plasma were able to affect HDL catabolism in an “in vitro” model of cultured hepatoma cells (HepG2).
Results: plasma HDL-C levels in the population correlated negatively with myristic acid (C14:0,
b ¼ 0.24, p < 0.01), oleic acid (C18:1n9, b ¼ 0.22, p < 0.01) and cis-11-Eicosenoic (C20:1n9, b ¼ 0.19,
p ¼ 0.01) and positively with palmitoleic acid (C16:1, b ¼ þ0.19, p ¼ 0.03). HepG2 cells were conditioned
with FA before evaluating HDL binding kinetics, and only C14:0 increased HDL binding by a non-
saturable pathway. After removal of heparan sulphate proteoglycans (HSPG) by heparinases HDL bind-
ing dropped by 29% only in C14:0 conditioned cells (p < 0.05). C14:0 showed also the highest inter-
nalization of HDL-derived cholesteryl esters (CE, þ32% p ¼ 0.01 vs. non-conditioned cells).
Conclusions: C14:0 was correlated with decreased plasma HDL-C levels in a Mediterranean population.
C14:0 might reduce HDL-C levels by increasing HDL trapping to cell surface HSPG and CE stripping from
bound HDL. Other mechanisms are to be investigated to explain the effects of other FA on HDL
metabolism.
© 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Dietary supplementation of unsaturated fatty acids (FA) protects
against atherosclerosis and cardiovascular (CV) events [1]. The ef-
fects of dietary FA on the lipid metabolism have been widely
investigated: mono- and poly-unsaturated FA (MUFA/PUFA)Medicine, Policlinico “Paolo
.
rna).
lo Giaccone”, Via del Vespro,
rved.supplemented to the diet were effective in lowering total choles-
terol (TC) and LDL cholesterol (LDL-C), while saturated FA (SFA)
increased TC and LDL-C [2,3]. HDL cholesterol (HDL-C) showed a
slight decrease with PUFA dietary supplementation [3] or a slight
increase with any FA in other studies [2]. Plasma levels of PUFA, but
not SFA, were associated with lower apolipoprotein AI (apo-AI) and
HDL-C levels in the Framingham study, but with different features
in men and women [4]. Animal models showed inconsistent re-
sults. PUFA and MUFAwere both effective in decreasing the TC and
LDL-C levels compared to SFA in some models, but HDL-C levels
were decreased mainly by PUFA [5,6].
The control of HDL-C plasma levels involves different pathways
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apoAI and apoAII, and lipidation of the nascent lipoproteins by
speciﬁc lipid transporters (as ATP-binding cassette, sub-family A
member 1, ABCA1 and scavenger receptor class I type B1, SRB1), ii)
remodeling of circulating HDLs by plasma enzymatic activities as
lipoprotein lipase (LPL), hepatic lipase (HL) endothelial lipase (EL),
lecithin cholesterol transfer protein (LCAT) and/or lipid transport
proteins, as cholesteryl ester transfer protein (CETP), and phos-
pholipids transfer protein (PLTP), iii) clearance from the circulation
via speciﬁc cell membrane receptors, such as the SR-B1. There are
evidences suggesting that plasma non-esteriﬁed FA (NEFA) control
several key steps of HDL metabolism. Unsaturated NEFA down-
regulate ABCA1 and ABCG1 genes expressions [8]. NEFA also
modulate LPL [9], CETP [10] and HL [11]. The control of the lipid
metabolism by NEFA is mediated by the modulation of the Perox-
isome ProliferatoreActivated Receptors (PPARs) activities [12]. The
hepatic HDL receptor, SR-B1, appears to be under the control of
PPAR gamma-RXR heterodimer [13], nevertheless studies evalu-
ating the regulation of SR-B1 expression gave contrasting results.
Unsaturated FA in macrophages and liver cells did not alter SR-B1
expression [8] while rats fed with PUFA increased it [14].
The ﬁrst aim of this paper was to evaluate the relationship be-
tween plasma NEFA composition and HDL-C levels in a population
of Southern Italy from the “Ventimiglia Hearth Study”, an epide-
miological project started in 1989 with the aims to survey a typical
rural Mediterranean population in search of CV risk factors and to
register CV events over the years of follow up [15,16]. In the second
part of the study the NEFA signiﬁcantly correlated with plasma
HDL-C levels in this populationwere investigated “in vitro” for their
ability to modify HDL catabolism using cultured liver hepatoma
cells (HepG2). HDL binding and/or internalization into liver cells
were investigated after conditioning them with different synthetic
FAs. Data concerning the effect of different FAs on SR-B1 expression
and the heparan sulphate proteoglycans (HSPG) contribution to
“in vitro” HDL catabolism are also presented.
2. Methods
2.1. Study subjects
The subjects of the present study were selected from the data-
base of the Epidemiological project “Ventimiglia di Sicilia Heart
Study” [15,16]. About nine hundreds sera were stored in
2002e2003 for epidemiologic analyses and were analyzed within a
year from storage. In the present study, a subset of the sampled
population was selected using a block randomization procedure in
order to represent the original population in terms of age, gender,
BMI and type 2 diabetes mellitus distribution. Randomization was
performed with a 1:5 ratio, so that about two hundreds subjects
were selected for subsequent analyses.
The adopted procedures were in accordance with the Helsinki
Declaration of 1975, as revised in 1983 and were approved by the
Ethical Committee of the University of Palermo. All the subjects
gave their informed consent to participate to the study.
2.2. Laboratory analyses
Lipid proﬁle, blood glucose and other relevant biochemical pa-
rameters were measured using standard enzymatic-colorimetric
procedures (Roche Diagnostics, Basel Switzerland) on a COBAS
MIRA plus auto-analyzer (Roche Diagnostics, Basel Switzerland).
LDL-C was calculated by the Friedewald formula. Detailed pro-
cedures of the epidemiological study methodologies are described
elsewhere [15,16].
NEFA were measured in the plasma by Gas Chromatography-Mass Spectrometry (GC/MS). NEFA were extracted from the
plasma adapting the method described by Lepage and Roy [17].
Plasma aliquots used for NEFA determination were stored after
addition of a mixture of an anti-proteases cocktail (Roche Diag-
nostic, Basel Switzerland) and 50 mM beta-hydroxy-toluene and
analyzed within a year from storage. Random samples were occa-
sionally retested to check for consistency of NEFA determination
after prolonged storage. Twenty ﬁve mL of plasma were used, since
the recovery of NEFA was linear up to 50 mL of plasma (data not
shown). The extraction procedure was checked for possible release
of fatty acids from triglycerides by spiking 5 mL of Glyceryl
Tri(hexadecanoate-1-13C), (Sigma Aldrich, MO, U.S.A.) in some
samples. The amount of 1e13C hexadecanoate (C16:0, palmitate)
released during the extraction procedure was negligible (data not
shown). Extracted NEFA were converted to methyl ester (FAME)
and injected in a Hewlett Packard (Palo Alto, CA, U.S.A.) 5960 Gas
chromatograph equipped with a 100 m  0.25 mm SP2560 column
(Supelco, Bellefonte, U.S.A.) and coupled to a Hewlett Packard 5973
inert Mass spectrometer. GC/MS conditions were: injection split to
a 1:30 ratio, injector temperature 180 C. The oven initial temper-
ature was 80 C for 4 min, and then it increased to 220 C at 8 C/
min and remained at 220 C for 32 min. All reagents and standards
were purchased from SigmaeAldrich (SigmaeAldrich, MO, U.S.A.).
MS was used in Single ion monitoring (SIM mode). Eleven m/z
characteristic of saturated, mono-di- tri-tetra-enoic or n-enoic fatty
acids were selected as described in the “AOCS lipid library” site
according to Christie W. et al. (http://lipidlibrary.aocs.org/ms/
masspec.html).
Calibration curves were obtained by using true fatty acids
standards (FAME, Supelco, SigmaeAldrich), heptadecanoic acid
(C17:0) was used as internal standard (SigmaeAldrich). All cali-
bration curves were highly linear between 0 and 20 mg of injected
FAME, (all Pearson's R's were >0.996, data not shown); all cali-
bration points were prepared in triplicate spiking normal plasma
with scalar amount of standards and the curves was accepted if the
coefﬁcients of variation for the repeated measures were below 5%
(data not shown).
2.3. Lipoproteins isolation and ﬂuorescent labeling
Normal lipoproteins were isolated from a large pool obtained by
young healthy blood donors. Plasma was aliquoted and stored after
the addition of the anti-proteases and anti-oxidant cocktail
described before. Plasma HDL fractions were obtained by sequen-
tial ultracentrifugation in the 1.063e1.210 g/mL density range in a
L90 K Optima BeckmaneCoulter Ultracentrifuge (Beckman Coulter,
Fullerton, CA, U.S.A.). HDL particles were labeled with DIL (di-
octadecyl-indo-carbocyanine iodide) as described elsewhere [18].
In order to label HDL CE, recombinant HDLs containing BODIPY
FL12 (a ﬂuorescent analog of cholesteryl esters (CE) fromMolecular
Probes-Life Technologies, Eugene, (OR) U.S.A.) were prepared as
described elsewhere [19]. The BODIPY FL12 molecule is actively
hydrolyzed within lysosomes, but not by cholesteryl esterase.
2.4. Cell cultures and FA conditioning
HepG2 hepatoma cells were grown at 37 C, 5% CO2, in Dul-
becco's modiﬁed Eagle's medium (DMEM glutamax, Gibco BRL,
Gaithersburg, Maryland, United States) supplemented with 10%
Fetal Bovine Serum, 100 U/mL penicillin and 100 mg/mL strepto-
mycin (Gibco BRL), 1% non essential amino acids. Cells were grown
to sub-conﬂuence and seeded in 6 or 24 wells plates (Corning Life
Sciences, MA, U.S.A.) as speciﬁed. In conditioning experiments FA
were ﬁrst complexed to Bovine Serum Albumin (BSA, Sigma-
eAldrich, St. Louis, MO, U.S.A.) mixing a solution of 100 mM FA in
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55 C for 15 min. The complexed FA were supplemented in the
medium to achieve 0.5 mM in 1% BSA, or 0.25 mMwhen indicated.
Non-conditioned cells were supplemented with BSA alone. Five
fatty acids were used in all experiments: myristic acid (C14:0),
palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1n9),
linoleic acid (C18:2n6), all from SigmaeAldrich.2.5. Fluorescent HDL binding to cells surface in HepG2 hepatoma
cells
HepG2 cells were seeded in 24 wells plates (5 104 cellswell)
and grown to sub-conﬂuence. Eighteen hours before the experi-
ments, cells were supplemented with different FA at 0.5 mM con-
centration in 1% BSA [20]. The assays were performed in triplicate.
Cells were incubated for 2 h with increasing amount of DIL-HDL
(from 0 to 120 mg/mL) at 4 C to evaluate HDL binding. At the end
of the incubation, wells were washed trice with cold phosphate
buffer solution (PBS) plus 2 mM CaCl2, 1 mM MgCl, and cells were
lysed in 0.1 N NaOH, 1% sodium dodecyl sulphate (SDS) for 1 h at
37 C. Cell lysates aliquots were used for protein commercial de-
terminations (BCA micro, Pierce Biotechnology, U.S.A.). Lysates
were cleared by centrifugation at 14.000 rpm in a microfuge at 4 C
and cell incorporated ﬂuorescence was read on a RXL10 Shimadzu
ﬂuorometer equipped with a cell holder (Shimadzu Corporation,
Tokyo, Japan) at excitation 535 nm and emission 570 nm. DIL-HDL
binding was calibrated against a DIL-HDL scale in lysis buffer. Re-
sults were calculated as ng of incorporated DIL-HDL/mg of cell
proteins.2.6. Fluorescent HDL binding to cell surface in HepG2 hepatoma
cells after heparinases treatment
To evaluate the role of the HSPG in HDL surface binding to FA
conditioned cells, cultures were treated with heparinases to disrupt
the cell surface HSPG matrix. The assays were performed in tripli-
cate. Four hours before the HDL binding experiment, Heparinase I
and III (SigmaeAldrich), 4 IU/mL each, were added to the cells as
described elsewhere [21]. A single dose of DIL HDL (40 mg/mL) was
administered to the cells after heparinases treatment according to
the protocol described previously.
In the same setting HDL binding was evaluated with and
without heparinases treatment, and the result of the treatment was
expressed for every FA as percent loss of binding relative to the HDL
binding without heparinases treatment.2.7. Fluorescent HDL-CE internalization into HepG2 hepatoma cells
BODIPY FL-12 labeled-HDL were prepared as described above.
HepG2 cells were seeded in 24wells plates and conditionedwith FA
as described above. The assays were performed in triplicate. Cells
were incubated with 30 mg/mL of ﬂuorescent HDL for 4 h at 37 C.
After incubation, cells were washed twice with PBS and trypsinized
in 0.05% trypsin, 0.02% EDTA (SigmaeAldrich). Trypsin was inacti-
vated by adding culture medium and cells were centrifuged at
1000 g for 5 min. After two washes with cold PBS plus 2 mM CaCl2,
1 mM MgCl, cells were suspended in PBS and subjected to cell
ﬂuorocytometry in a FACSCalibur (BectonDickinson, San Jose, CA,
U.S.A.) ﬂuorocytometer using the Fl1 channel. Median ﬂuorescence
intensities (MFI), corrected for cells auto-ﬂuorescence, were ob-
tained by CellQuest Pro software (BD) and they were considered as
measures of internalized CE. Data of CE internalization were
expressed as proportions of non-conditioned (BSA) cells.2.8. SR-B1 protein expression on HepG2 hepatoma cells membrane
by immuno-cytoﬂuorimetry
The HepG2 were grown in 6 well plates to sub-conﬂuence and
conditioned for 24 h with FA as described above. The assays were
performed in triplicate. After conditioning, cells werewashed twice
with PBS plus 2 mM CaCl2, 1 mM MgCl and trypsinized in 0.05%
trypsin, 0.02% EDTA (Trypsin-EDTA solution 1, SigmaeAldrich).
Trypsin was inactivated by adding cell culture medium and the
cells, collected in tubes, were centrifuged at 1000 g for 5 min. After
two washes with PBS, the cells were suspended in 1% BSA in PBS.
The cellular suspensions were incubated overnight at 4 C with a
1:50 dilution of rabbit polyclonal anti SR-B1 antibody (donated
kindly by Prof. Schonfeld G., Washington University di St. Louis, MO
- U.S.A.) in PBS and 1% BSA followed by a 1 h incubation with a
1:100 dilution of a Alexa-ﬂuor 488 conjugated secondary anti-
rabbit antibody (Life technologies). After a ﬁnal wash, Cells were
analyzed by the FACSCalibur using the Fl1 channel and analyzed by
CellQuest Pro software (BD) as before. Median values of ﬂuores-
cence intensity (subtracted of cells auto-ﬂuorescence) were
considered as measures of surface SR-B1. Data were expressed as
proportions of BSA conditioned cells.
2.9. Statistics
Differences in clinical and biochemical parameters in the pop-
ulation study were evaluated by Student's T-test. Univariate cor-
relations were evaluated by Pearson's R, while independent
correlations were evaluated by multiple regression analysis (MRA)
after adjustment for confounders (age, gender, BMI), using a step-
forward option. A set of step-backward MRA were performed in
parallel with similar results (data not shown). Statistics were
calculated by the SYSTAT 12 software (SYSTAT corp., CA, U.S.A.).
Kinetics curves of DIL-HDL binding to HepG2 cells were ﬁtted
with a MichaeliseMenten (MM) equation model modiﬁed by
adding a linear component in order to take into account a non-
speciﬁc, non-saturable HDL binding pathway (Supplementary
Equation (1)). Curve ﬁtting was performed using the nls2 (“Non-
linear regression with brute force”) package from the R statistic
software (https://cran.r-project.org/web/packages/nls2/index.
html). The software calculated estimates of MM parameters with
relative standard errors of estimated: Bmax expressed the amount
of DIL-HDL bound to saturable sites on the cell surface, Km
expressed the MM constant, and Kasp expressed the linear non-
speciﬁc binding constant (see Supplementary Equation (1)). Dif-
ferences in the estimated kinetics parameters between non-
conditioned cells and FA conditioned cells were evaluated from
calculated means and SD by Student's T test.
3. Results
3.1. Relationship between HDL-C levels and plasma FA in a
Mediterranean population
Table 1 shows clinical data and NEFA proﬁle of the study pop-
ulation divided according to gender. The table shows that the only
biochemical parameters signiﬁcantly differing between males
(n ¼ 103) and females (n ¼ 97) were TC, HDL-C and TG (nearly
signiﬁcant, p ¼ 0.06), all of them higher in females. TG/HDL-C (mg
to mg ratio) was higher in males. No differences in plasma NEFA
proportions were detectedwith the exception of C18:2n6 (p¼ 0.03)
and aggregated PUFA (p ¼ 0.02) slightly higher in females.
Table 2 shows the correlations between HDL-C plasma levels
and plasma NEFA relative amounts. At univariate analysis (column
2), HDL-C levels were correlated positively with PUFA (þ0.28,
Table 1
Clinical and Biochemical parameters in the study sample.
Parameter Males (n ¼ 103) Females (n ¼ 97) T-test pa
Age (years) 55.43 ± 19.38 54.62 ± 18.95 0.77
BMI (kg/m2) 27.96 ± 5.16 29.37 ± 6.67 0.10
Waist(cm) 95.29 ± 12.27 92.23 ± 14.86 0.12
Systolic BP (mm/Hg) 126.73 ± 21.58 126.19 ± 21.54 0.86
Diastolic BP (mm/Hg) 77.56 ± 10.09 76.36 ± 9.42 0.40
Total cholesterol (mmol/L) 4.84 ± 0.91 5.15 ± 1 0.02
Triglycerides (mmol/L) 1.32 ± 0.75 1.13 ± 0.57 0.06
HDL cholesterol (mmol/L) 1.00 ± 0.3 1.18 ± 0.3 <0.01
LDL cholesterol (mmol/L) 3.21 ± 0.76 3.4 ± 0.81 0.10
Fasting blood glucose (mmol/L) 5.01 ± 1.29 4.99 ± 1.11 0.91
C reactive protein (mg/dL) 0.31 ± 0.33 0.38 ± 0.71 0.34
TG/HDL-C (mg/mg ratio) 3.7 ± 4.21 2.37 ± 1.39 <0.01
plasma NEFA (proportion)
C14:0 (myristic) 0.009 ± 0.005 0.008 ± 0.004 0.2
C16:0 (palmitic) 0.229 ± 0.044 0.219 ± 0.03 0.09
C16:1 (palmitoleic) 0.015 ± 0.009 0.015 ± 0.006 0.83
C18:0 (stearic) 0.09 ± 0.031 0.085 ± 0.024 0.26
C18:1n9 (oleic) 0.208 ± 0.051 0.197 ± 0.042 0.10
C18:2n6 (linoleic) 0.342 ± 0.104 0.372 ± 0.081 0.03
C18:3n6 (g-linolenic) 0.003 ± 0.001 0.003 ± 0.001 0.62
C18:3n3 (a-linolenic) 0.001 ± 0.001 0.001 ± 0.001 0.56
C20:1n9 (cis-11-Eicosenoic) 0.028 ± 0.018 0.025 ± 0.011 0.21
C20:2 (cis-11,14-Eicosadienoic) 0.002 ± 0.001 0.002 ± 0.001 0.74
C20:3n6 (cis-8,11,14-Eicosatrienoic) 0.019 ± 0.006 0.02 ± 0.005 0.20
C20:4n6 (Arachidonic) 0.003 ± 0.001 0.003 ± 0.001 0.67
C20:5n3 (cis-5,8,11,14,17-Eicosapentaenoic) 0.005 ± 0.003 0.005 ± 0.003 0.42
C22:6n3 (cis-4,7,10,13,16,19-Docosahexaenoic) 0.018 ± 0.008 0.018 ± 0.007 0.55
Aggregated NEFA
SFA 0.32 ± 0.06 0.31 ± 0.04 0.07
MUFA 0.22 ± 0.05 0.21 ± 0.04 0.11
PUFA 0.42 ± 0.09 0.44 ± 0.07 0.02
Biochemical parameters and plasma NEFA proﬁles in the Ventimiglia Heart Study population divided by gender.
a Student's T-test p-values, Males vs. Females.
Table 2
Correlation of plasma fatty acids composition with HDL cholesterol levels.
Plasma NEFA Pearson's R (p value)a Std coefﬁcient (p value)b
C14:0 (myristic) 0.27 (<0.01) 0.24 (<0.01)
C16:0 (palmitic) 0.17 (0.06)
C16:1 (palmitoleic) 0.09 (0.18) þ0.19 (0.03)
C18:0 (stearic) 0.08 (0.27)
C18:1n9 (oleic) 0.27 (<0.01) 0.22 (<0.01)
C18:2n6 (linoleic) þ0.28 (<0.01) Excl (0.96)
C18:3n6 (g-linolenic) 0.01 (0.89)
C18:3n3 (a-linolenic) 0.12 (0.12)
C20:1n9 (cis-11-Eicosenoic) 0.24 (<0.01) 0.19 (0.01)
C20:2 (cis-11,14-Eicosadienoic) 0.04 (0.58)
C20:3n6 (cis-8,11,14-Eicosatrienoic) þ0.05 (0.47)
C20:4n6 (Arachidonic) þ0.10 (0.16)
C20:5n3 (cis-5,8,11,14,17-Eicosapentaenoic) þ0.03 (0.64)
C22:6n3 (cis-4,7,10,13,16,19-Docosahexaenoic) 0.01 (0.87)
Aggregated NEFA
Saturated NEFA 0.17 (0.01) Excl(0.61)
Mono-unsaturated NEFA 0.27 (<0.01) Excl(0.68)
Poly-unsaturated NEFA þ0.28(<0.01) Excl(0.96)
a Pearson's R Univariate correlation.
b Multiple regression analysis adjusted for age and gender. Statistical p values in brackets.
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and negatively with MUFA (0.27, p < 0.01) mainly because of
C18:1n9 (0.27, p < 0.01). SFA correlated negatively, but not
signiﬁcantly, with HDL-C levels because of the signiﬁcant C14:0
correlation with HDL-C levels (0.27, p < 0.01), while C16:0 and
C18:0 did not correlate with HDL-C levels. NEFA that were corre-
lated with HDL-C at univariate analysis were included in a multiple
regression analysis (MRA) that also included the most abundant
plasma NEFA, using age and gender as covariates. The MRA showed
that only C14:0 (b ¼ 0.24 p < 0.01), C18:1n9 (b ¼ 0.22 p < 0.01)
and C20:1n9 (cis-11-Eicosenoic, b ¼ 0.19 p < 0.01) wereindependently and negatively correlated with HDL-C levels, while
C16:1 was positively correlated (b¼þ0.19 p¼ 0.03) at MRA but not
at univariate analysis. Correlation coefﬁcients were not signiﬁ-
cantly affected by measures of adiposity, as B.M.I. and waist
circumference (Supplementary Tables Se1).
3.2. Effects of FA conditioning on HDL catabolism in liver cultured
cells (HepG2)
The FA used to condition HepG2 cells were selected among
those found correlated with HDL-C levels in the population study or
D. Noto et al. / Atherosclerosis 246 (2016) 50e5654resulted more abundant in the plasma with the exception of C20:1,
because of the presence of C18:1 as similar MUFA. FA were tested
“in vitro” in a liver hepatoma HepG2 cells model. HDL binding to
cell surface was evaluated after conditioning the cell with single FA.
Fig. 1 shows the kinetics of the DIL-HDL binding to cells surface
after conditioning the cells with different FA. Individual FA data,
ﬁtted curves according to the ﬁrst-order MichaeliseMenten model
and estimated kinetic parameters are presented in Supplementary
Fig. S1eS5. A summary of kinetics estimates is shown in Table 3.
The data show that no FA signiﬁcantly increased HDL binding by
increasing the amount of HDL bound to saturable sites of cell
membrane (Bmax), while C14:0 showed a peculiar behavior,
increasing the HDL surface binding by increasing the amount of
HDL bound to non-saturable sites (slope of linear ﬁtting,
kasp þ 43%, p < 0.001) on cell surface. All FA but C18:0 seemed to
increase the afﬁnity for cell surface binding sites (decrease of kmm
constant).3.3. HSPG contribution to HDL catabolism in liver cultured cells
(HepG2) after conditioning with FA
In order to test the hypothesis that the HSPG moiety of hepa-
tocytes surface might account for the peculiar kinetics of C14:0, DIL
labeled HDL were competed with liver cells before and after
treatment with heparinase I and III, an enzyme mixture able to
hydrolyze cell surface HSPG. Fig. 2 shows that heparinases abol-
ished about the 30% (p¼ 0.001) of total HDL binding in cells treated
with C14:0, while no effect could be detected in other FA condi-
tioned cells. All other FA reduced the loss of HDL binding after HSPG
stripping shown in non-conditioned cells (14%, p ¼ 0.01), and
C18:1n9 even increased (not signiﬁcantly) HDL binding (per mg of
cell protein) after HSPG cleavage (þ9%, p ¼ 0.18).Fig. 1. DIL-HDL binding to HepG2 cells conditioned with FA. HDL binding curves were
obtained after conditioning the cells with the FA shown in the legend (see methods).
Error bars ¼ SD of triplicates. X axis ¼ DIL HDL concentration in the cell medium. Y-
axis ¼ DIL HDL bound to HepG2 cell surface.3.4. Effects of FA conditioning on HDL-CE internalization in liver
cultured cells (HepG2)
Internalization of ﬂuorescent CE was performed by incubating
FA-conditioned cells with recombinant HDL containing BODIPY-
FL12. Internalized CE were measured by ﬂow cell ﬂuorocy-
tometry. FA did not modify the CE internalization with the excep-
tion of C14:0 that signiﬁcantly increased CE internalization by 32%
(p ¼ 0.01) as shown in Table 3.
3.5. Effects of FA conditioning on SR-B1 cell-surface expression on
liver cultured cells (HepG2)
The effect of FA on SR-B1 cell surface expression was evaluated
by immuno-cytoﬂuorimetry on FA conditioned HepG2 cells. No
signiﬁcant differences in SR-B1 expression were found. Still, SFA
(C14:0, C18:0) showed a rough 20% reduction of SR-B1 expression,
while C18:1n9 showed a non signiﬁcant þ12% increase (Table 3,
p ¼ 0.27).
4. Discussion
In this paper we ﬁrst investigated how plasma NEFA composi-
tion correlated with plasma HDL-C levels in a free living population
of Southern Italy. This population is a typical Mediterranean pop-
ulation following a “modern” version of the Mediterranean diet
with a lower content of ﬁbers and an excess of introduced calories
in comparison with the “traditional” diet [15]. Olive oil constitutes
the majority of dietary fat. This population is characterized by a
high prevalence of obesity [15,16] and metabolic syndrome (MetS)
[16] that also represents a relevant risk factor for CV events
observed during a 15 years follow-up [16]. More, the average HDL-C
levels of this population are slightly lower than the Italian levels
[15,16].
We found that HDL-C levels of this population correlated posi-
tively with the proportion of plasma PUFA and negatively with SFA.
Among individual NEFA, HDL-C levels strongly and negatively
correlated with C14:0, C18:1n9 and C20:1n9, and positively with
C16:1. Different studies showed that C14:0 positively correlated
with plasma HDL-C levels, and a large meta-analysis including 60
dietary intervention studies concluded that the increase of HDL-C
due to SFA progressively decreases with the elongation of the
acyl chain, being maximal for C12:0 (lauric acid) and not relevant
for C18:0 [2]. The dietary supplementation of C14:0 did not produce
a signiﬁcant raise in HDL-C levels in the same study [2]. Another
large meta-analysis showed that the isocaloric replacement of
C18:0 with C12:0/C14:0/C16:0 did not signiﬁcantly raise the HDL-C
levels [22]. These contrasting results might be explained by the
heterogeneous characteristics of the studied populations. The
population of the present study shows a high prevalence of MetS
[16]. High levels of C14:0 were associated to the risk of MetS with
an odds ratio of 5.84 in women and 2.23 in men in study of obese
subjects [23]. It is possible that the inverse relationship between
C14:0 and low HDL-C in obese subjects might be explained by the
increase of MetS induced by C14:0, since low levels of HDL-C are
characteristic of MetS patients [16].
Another explanation of these results might be related to the
choice to assay NEFA instead of total FA in the present study. Di-
etary FA modify not only NEFA but also total FA composition, and
the modiﬁcation of esteriﬁed FA proﬁle may result a better pre-
dictor of HDL levels than NEFA proﬁle.
C18:1n9 was correlated with lower levels of HDL-C in our study,
being oleic acid highly represented in the Mediterranean diet of
this population [15], while C18:2n6 was associated with higher
HDL-C levels, though the latter association was not maintained at
Table 3
HDL-CE uptake and SR-B1 cell-surface expression in HepG2 Hepatoma cells conditioned with FA.
HDL binding kinetics parameters Cytoﬂuorimetry
Fatty acids Bmaxa Kmmb Kaspc Fluorescent CE internalizationd Cell surface SR-B1 expressione
C0 100 ± 42 100 ± 87 100 ± 29 100 ± 3 100 ± 13
C14:0 97 ± 27 (0.83) 20 ± 57 (0.006) 143 ± 23 (<0.001) 132 ± 8 (0.01) 82 ± 20 (0.27)
C16:1 109 ± 22 (0.43) 41 ± 47 (0.03) 90 ± 17 (0.31) 101 ± 11 (0.51) 99 ± 11 (0.95)
C18:0 91 ± 42 (0.59) 55 ± 118 (0.25) 115 ± 32 (0.18) 96 ± 4 (0.316) 86 ± 13 (0.28)
C18:1n9 96 ± 19 (0.79) 31 ± 44 (0.01) 112 ± 16 (0.171) 97 ± 7 (0.67) 112 ± 10 (0.26)
C18:2n6 96 ± 17 (0.79) 35 ± 39 (0.01) 103 ± 13 (0.70) 96 ± 4 (0.66) 101 ± 10 (0.87)
Data are expressed as percent of non-conditioned cells ± SD, Student's T test vs. non-conditioned cells, and p-value in brackets.
a Bmax ¼ amount of DIL-HDL bound to saturable cell surface sites.
b kmm ¼ Michaelis Menten constant.
c Kasp ¼ linear non speciﬁc binding constant (see methods).
d Cell internalization of BODIPY FL12 (cholesteryl ester ﬂuorescent analog).
e SR-B1 cell surface expression evaluated by immuno-cytoﬂuorimetry.
Fig. 2. DIL-HDL binding to HepG2 cells conditioned with FA after HSPG removal by
heparinases treatment. HDL binding values were obtained after conditioning the cells
with the FA shown in the legend (see methods). Error bars ¼ SD of triplicates. X
axis ¼ “before” indicates HDL binding before heparinases treatment, “after” indicates
HDL binding after the treatment. Y-axis ¼ DIL HDL bound to HepG2 cell surface  mg
of cell proteins. The legend also shows the percent loss of binding after heparinases
treatment and the relative Student's t test p-value, (before vs. after heparinases
treatment).
D. Noto et al. / Atherosclerosis 246 (2016) 50e56 55multivariate analysis.
We tried to understand if an altered hepatic catabolism of HDL
induced by FA might contribute to explain the results found in the
population study. We used an “in vitro” model of cultured hepa-
toma cells conditioned with those FA that resulted correlated (as
NEFA) with plasma HDL-C levels in the population study (Table 2),
or that resulted very abundant in the plasma, as C18:0. We decided
to exclude C20:1n9 to avoid over-representation of MUFA, being
C18:1 about ten-times more abundant than C20:1 and very similar
to it in terms of chain length.
The main result of the “in vitro” part of the study consisted in
the ﬁnding that myristic acid modiﬁed the HDL binding to liver
cultured cells in a peculiar manner. C14:0 increased the non-
speciﬁc binding of HDL to cell surface and it did not affect the
saturable receptor-mediated binding (Fig. 1, Table 2 andSupplementary Figs. Se1). The increase of HDL binding caused by
C14:0 cell conditioning showed a linear doseeresponse effect be-
tween 0.25 mM and 1 mM of supplemented C14:0 (data not
shown). The increase of HDL binding is partly explained by the
presence of HSPG, since their removal by heparinases treatment
determined roughly a 30% loss of HDL binding activity in compar-
ison with non-conditioned cells and all the other FA (Fig. 2). C14:0
conditioning also increased the internalization of ﬂuorescent CE
contained in synthetic HDL3 by þ32% (Table 3). HSPG are an
essential part of the lipoproteins-CE removal from the bloodstream.
HDLs are trapped by the PG matrix surrounding the hepatocytes
and stripped of their CE content by the HL in exchange of tri-
glycerides (TG) [7]. This mechanism could explain why CE inter-
nalization in the hepatic cells was increased by C14:0, though this
result is not consistent with previous reports. In a dietary inter-
vention study, a diet rich in C14:0 and other SFA was associated
with a reduced activity of HL, resulting in a positive correlationwith
LDL size [24]. Also, a diet supplementationwith SFA in monkeys [5]
determined an increase of plasma HDL-C and a decrease of CE
hepatic content, suggesting that CE internalization was not
increased but reduced in those models. The difference between the
metabolism of the animal models and that of isolated cultured cells
may explain this apparent discrepancy. Interestingly, high C14:0
levels were found associated with lower Lipoprotein(a) [Lp(a)]
plasma levels [25]. Since C14:0 is probably not able to affect apo(a)
synthesis, being apo(a) levels under strict genetic control [25], it is
plausible that C14:0 reduces Lp(a) levels by increasing Lp(a) trap-
ping by HSPG, a relevant mechanism involved in Lp(a) catabolism
[26]. Our results suggests that C14:0 increases the catabolism of
HDL-CE, Lp(a), and probably VLDL by modifying the proteoglycan
extracellular matrix. We also evaluated the effect of FA on SR-B1
protein expression on the liver cells surface. We measured the
surface-exposed SR-B1 by immuno-cytoﬂuorimetry and we found
that C14:0 and C18:0 showed a trend toward the decrease in SR-B1
expression (roughly by 20% though not signiﬁcant, Table 3). If
conﬁrmed and validated, this result would be in accord with
another study showing reduced a SR-B1 expression in hamsters
treated with C14:0 [27]. Dietary interventions enriched in C14:0
increased circulating HDL-3 particles [28,29], that are generated by
SR-B1 from nascent HDL [7], but the increase of HDL3 in these
studies has been explained by the impairment of the HDL3>HDL2
conversion due to the lecithin-cholesterol acyl transferase (LCAT)
inhibition induced by C14:0 [29].
All the results concerning the other investigated FA are less
straightforward to interpreter. C18:1n9 was associated with lower
HDL-C levels in the population study conﬁrming large association
studies [2,3]. Themechanismmight be related to an increase of HDL
clearing related to SR-B1. We observed a not signiﬁcant 12%
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supported by neither an increase in HDL particles bound to cell
surface nor an increase in CE internalization under C18:1n9 cells
conditioning. C18:1n9 is a powerful PPARs activator [12], so it is
possible that the negative correlationwith plasma HDL levels might
be related to the effect of PPARs activation in liver cells, but it is not
clear why C18:2n6, also a potent PPARs activator, did not show any
relevant correlation with SR-B1 in this study.
The main limit of this study is that the “in-vitro” experiments
were focused only on HDL particles catabolism by liver cells, and it
is not always possible to ﬁnd a straight correlation between the
data obtained “in-vivo” from human studies and the limited cata-
bolic aspects elucidated by the “in-vitro” experiments. In spite of
this limitation, a novel mechanism by which C14:0 affects HDL-C
catabolism is clearly demonstrated in cultured hepatoma cells.
In conclusion, we showed that myristic acid is negatively
correlated with plasma levels of HDL-C in a Mediterranean popu-
lation characterized by an excess of obesity and metabolic syn-
drome. We suggest that part of this correlation might be explained
by an increase of HDL binding to hepatic HSPG and subsequent
cholesteryl esters stripping by proteoglycans-bound lipases. Our
study reinforces the necessity to reduce overweight and to decrease
the amount of dietary saturated fats in order to improve pop-
ulation's health.
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